Dear Friends,

A recent FDA decision denied approval of a promising new treatment called RP1 for advanced melanoma—one that showed encouraging results for patients who had failed first-line therapy. Read more about the denial here. Because the treatment could save lives, we feel compelled to appeal to the FDA.

We need your help.

Your experience with melanoma — whether you are a patient, family member, friend, or other interested party — can help us show the FDA why new treatment approvals matter in general, and this one specifically. Our message is that while immunotherapy has been a breakthrough, many patients either do not respond or do so temporarily.

We need other viable treatment options. With 8,430 deaths from melanoma expected this year alone, we should not deny approval to viable treatments.

We’re collecting personal stories to include in our message to the FDA.

• If you face (or have faced) limited options for treatment or support(ed) someone who has, please tell us about it
• If your loved one has passed away from melanoma, please consider sharing your story
• If you or your loved one has survived first-line treatment, please tell us about your journey

You can sign your full name, sign partially (“Jen G. from CA”), or write anonymously. We will share your stories along with a letter from AIM and multiple melanoma and cancer advocacy groups urging reconsideration of this decision.

Share your story with us by filling out this form.

Your voice could help drive change for the melanoma community.

Thank you,

Sam Guild
President
AIM at Melanoma Foundation